Abstract library

19 results for "Pieri".
#216 Patients Treated for Well-Differentiated Neuroendocrine Tumors: A Study to Evaluate the Ratio of Patients Lost to Follow-up
Introduction: Well-differentiated neuroendocrine tumors (wdNET) are considered more indolent than other epithelial malignancies. Median survival for patients with G1/G2 NET can range from 33 to 223 months.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Rosine Guimbaud
#266 Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Chiara Zatelli
#524 Sunitinib in a MEN-1 Patient with Small Cell Neuroendocrine Tumor of the Thymus
Introduction: MEN-1 is an autosomal dominant disease caused by mutation of the oncosuppressor gene menin. MEN-1 is typically associated with hyperparathyroidism, islet cell tumors and pituitary adenomas, but it can also be associated with other neoplasms, such as thymic carcinoids.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Prof Giovannella Palmieri
#570 Lymph-Nodal Merkel Cell Carcinoma (MCC) in the Absence of Primary Tumor: Regression of the Primary or Lymph-Nodal Primitivity? Report of a Series with Favorable Prognostic Behavior
Introduction: MCC is a rare cutaneous neuroendocrine neoplasm with aggressive behavior, a high recurrence rate and, generally, poor prognosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Diego Ferone
#587 First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus.
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference:
Category: Basic
Presenting Author: MD Manuela Albertelli
#752 First In Vitro Study of Human Gastroenteropancreatic Neuroendocrine Tumors: Comparative Effect of Octreotide, Pasireotide and Everolimus
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Diego Ferone
#963 From E.L.I.O.S. (Educational Learning Investigational Observational Study) an Initial Update on Neuroendocrine Tumors (NETs) in the Southern Italy
Introduction: Elios is an Educational Learning Investigational Observational Study.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Salvatore Tafuto
#972 Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)
Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Antongiulio Faggiano
Keywords: NET, SSA, G1, G2, WHO classification
#1000 E.L.I.O.S. (Educational Learning Investigational Observational Study): An Initial Update on Neuroendocrine Tumors (NETs) in the Southern Italy
Introduction: Elios is an Educational Learning Investigational Observational Study.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Salvatore Tafuto
#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis
Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Alberto Bongiovanni
Keywords: GEP-NEC, chemotherapy